Taysha Gene Therapies Finalizes Equity Offering, Securing $187.4M Net; Grants 5M Share Option
TSHA has more than doubled off its 52-week low of $2.25 on elevated volume (4.3× avg).
Summary
Taysha Gene Therapies has finalized the pricing of its equity offering, expecting to raise approximately $187.4 million in net proceeds. The company also granted underwriters an option to purchase an additional 5 million shares. This financing event, which follows the proposed offering announced yesterday and subsequent pricing details, represents a material dilution of existing shareholders, potentially increasing the share count by over 10%. The capital raised is intended to fund operations and extend the company's cash runway beyond the previously stated 2028 timeframe.
At the time of this announcement, TSHA was trading at $6.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.25 to $7.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.